Dutch Pharma Stock News

If you are wondering whether DSM-Firmenich at around €59 still reflects its true worth, you are not alone, and this article is built to help you assess what that price might really represent. The stock has been through a rough patch, with the share price down 14.6% over the last 30 days and 37.4% over the past year. It is up 2.9% over the past week and down 14.3% year to date. Recent coverage around DSM-Firmenich has focused on its position in the broader materials and specialty ingredients...

On 12 March 2026, around 180 BTC worth approximately US$12.07 million were transferred from several anonymous addresses to Flow Traders, underlining its operational role in cryptocurrency liquidity provision. This sizeable Bitcoin inflow brings fresh attention to how Flow Traders’ digital asset activity interacts with its broader multi-asset liquidity model. We’ll explore how this large Bitcoin transfer to Flow Traders could influence its investment narrative, especially regarding digital...

IMCD (ENXTAM:IMCD) is back on watch after Evonik Industries AG expanded its Visiomer specialty methacrylates distribution partnership into the U.S., giving IMCD added exposure to a key specialty chemicals segment. See our latest analysis for IMCD. The U.S. Visiomer deal and recent leadership changes sit against a mixed share price picture, with a 4.25% 1 day share price return and 2.49% 7 day share price return contrasting with a 21.31% 30 day share price decline and a 41.08% 1 year total...

Event overview and why it matters Arcadis (ENXTAM:ARCAD) has secured two new contracts with the City of Los Angeles, covering work on the Los Angeles Convention Center Modernization and Expansion and the Department of Public Works Bureau of Engineering's Clean Water Program. The combined contract value exceeds €18 million, with €11 million tied to project and construction management support on the €2.5b convention center scheme and €7.5 million over five years for three stormwater initiatives...

ArcelorMittal (ENXTAM:MT) is back on investors’ radar after its recent share move, with the stock showing a mix of short term declines and longer term gains that invite a closer look. See our latest analysis for ArcelorMittal. That recent pullback, including a 4.22% one day share price decline and 11.43% 30 day share price return, sits against a stronger backdrop, with a 20.75% 90 day share price return and 66.18% one year total shareholder return. This suggests that earlier momentum is now...

Aalberts has completed the divestment of BROEN A/S, advancing its ‘thrive 2030’ repositioning plan. The company is running a significant share buyback programme alongside the transaction. ENXTAM:AALB last closed at €32.78. For you as an ENXTAM:AALB watcher, these moves relate directly to how Aalberts is reshaping its portfolio and capital structure. The share price stands at €32.78, with a 14.9% gain year to date and a 3.5% return over 1 year, while 3 year and 5 year returns show declines...

Basic-Fit (ENXTAM:BFIT) has wrapped up FY 2025 with second half revenue of €743.2 million and basic EPS of €0.34, alongside trailing 12 month revenue of €1.42 billion and basic EPS of €0.22. These figures frame the latest numbers in a broader earnings upswing. The company has seen revenue move from €630.44 million in the second half of 2024 to €743.2 million in the second half of 2025, while basic EPS shifted from €0.06 to €0.34 over the same periods. This sets up a story where higher sales...

Pharming Group (ENXTAM:PHARM) has wrapped up FY 2025 with fourth quarter revenue of US$106.5 million and basic EPS of US$0.008, while trailing twelve month figures stand at US$376.1 million in revenue and basic EPS of US$0.004. This frames a year where profitability on a full year basis edges into positive territory. The company has seen quarterly revenue move from US$92.7 million in Q4 2024 and US$74.8 million in Q3 2024 to US$106.5 million in Q4 2025. Over the same period, quarterly basic...

Envipco Holding (ENXTAM:ENVI) has reported its FY 2025 results with fourth quarter revenue of €23.8 million and a basic EPS loss of €0.03, while trailing twelve month revenue stands at €90.4 million with a full year basic EPS loss of €0.18. Over recent quarters the company has seen revenue move between €21.0 million and €23.8 million per quarter, while quarterly basic EPS losses have ranged from €0.03 to €0.07. This sets the scene for a story where strong reported revenue growth meets...

CVC Capital Partners (ENXTAM:CVC) has put up a punchy set of FY 2025 numbers, with first half revenue at €843.0 million and basic EPS of €0.54, set against trailing twelve month revenue of €1.85 billion and EPS of €1.11 that came with a very large year-on-year earnings increase and a net profit margin of 63.8% versus 14.4% the prior year. Over the past three reported halves, revenue has moved from €635.7 million with EPS of €0.05 in 1H 2024 to €926.2 million and EPS of €0.17 in 2H 2024,...

Recent share performance puts DSM-Firmenich in focus DSM-Firmenich (ENXTAM:DSFIR) has come onto investors’ radar after a series of weak returns, including an 18% decline over the past 3 months and a 41% negative total return over the past year. See our latest analysis for DSM-Firmenich. The recent weakness has been fairly persistent, with a 1-day share price return of a 1.91% decline and a 30-day share price return of a 17.06% decline adding to a 1-year total shareholder return of a 40.69%...

Fugro (ENXTAM:FUR) is back in focus after being hired for a geotechnical campaign at a 375 MW offshore wind project in Ireland, which highlights investor interest in its offshore site investigation expertise. See our latest analysis for Fugro. At a share price of €10.8, Fugro has had a mixed run, with a 27.13% 90 day share price return and 24.28% year to date share price return, set against a 17.72% 1 year total shareholder return decline and a 12.08% 3 year total shareholder return gain. The...

ABN AMRO Bank (ENXTAM:ABN) has released its 2025 Annual Report, giving investors fresh detail on value creation, capital allocation, cost efficiency, and sustainability commitments during a period of geopolitical and economic challenges. See our latest analysis for ABN AMRO Bank. At a share price of €28.25, ABN AMRO Bank has seen a 1-day share price return of 1.36% and a 7-day share price return of 1.07%. Its 30-day share price return of 10.26% and year to date share price return of 6.58%...

Allfunds Group: Earnings, Guidance and Dividend Draw Investor Focus Allfunds Group (ENXTAM:ALLFG) has put out a busy set of updates, combining full year 2025 results, fresh 2026 revenue guidance and a proposed cash dividend that together give investors more clarity on the stock. The company reported 2025 revenue of €621.9 million compared to €632.1 million a year earlier, with net income of €2.3 million after a net loss of €168.5 million in the prior year. For 2026, Allfunds is guiding to...

If you are wondering whether CSG is attractively priced or just a value trap, this article walks through what the numbers are really saying about the stock. CSG shares last closed at €29.43, with returns of a 4.4% decline over the past week, an 8.5% decline over the last month, and a 10.4% decline year to date, which may have caught the eye of investors watching for changing risk and return profiles. Recent coverage around CSG has focused on its overall positioning and fundamentals, giving...

ASML Holding (ENXTAM:ASML) is back in focus after news that Chinese chipmakers remain years behind its extreme ultraviolet lithography technology, and major customers are reportedly paying premiums to secure faster equipment deliveries. See our latest analysis for ASML Holding. Despite some recent volatility around geopolitical headlines and Chinese efforts to develop rival tools, ASML’s share price is at €1,198.8 with a roughly flat 30 day share price return and a 90 day share price return...

Royal Philips recently expanded its digital pathology portfolio with a fully cloud-enabled IntelliSite Pathology Solution on HealthSuite, powered by Amazon Web Services, to help laboratories scale digital diagnostics, streamline workflows, and support remote, collaborative case review. An interesting angle is how this move deepens Philips’ role in AI-ready, interoperable diagnostic platforms across radiology, cardiology, and pathology, reinforcing its push into end-to-end, cloud-based...

If you are wondering whether ArcelorMittal shares still offer value after a strong run, this article will walk through what the current price might be telling you. The stock trades at €49.46 after a 1.8% decline over the last 7 days and 3.4% decline over the last 30 days. The year to date return is 24.1% and the 1 year return is 75.2%, with 90.1% over 3 years and 134.4% over 5 years. Recently, news coverage has focused on ArcelorMittal in the context of broader materials and steel sector...

Fugro N.V. has reported full-year 2025 results showing sales of €1,848.1 million and a net loss of €20.5 million, while also announcing that Chief Financial Officer and Board of Management member Barbara Geelen will step down after the April 23, 2026 AGM and remain as an adviser until August 1, 2026. The combination of a swing from profit to loss and the upcoming CFO transition raises questions about how Fugro balances investment, cost control, and financial leadership as it pursues growth...

Why Van Lanschot Kempen’s latest earnings and dividend matter for shareholders Van Lanschot Kempen (ENXTAM:VLK) reported full year 2025 earnings alongside a fresh dividend announcement. This combination gives you new information on both the bank’s profitability profile and its approach to returning cash to shareholders. See our latest analysis for Van Lanschot Kempen. Investors appear to be reacting to the earnings and dividend news, with a 1-day share price return of 3.96% at a latest price...

Wondering whether ASML Holding is still reasonably priced after its strong run, or if the current share price is already baking in the story? This article is going to walk you through what the numbers are actually saying about value. ASML's share price recently closed at €1,200.00, with returns of 3.3% over 7 days, 0.5% over 30 days, 21.7% year to date, 91.6% over 1 year, 114.0% over 3 years and 171.3% over 5 years. This naturally raises questions about how much upside or risk is now priced...

The interim Amsterdam court ruling in the Macedonian Thrace Brewery case has put Heineken (ENXTAM:HEIA) under closer scrutiny, with investors weighing potential damages that could exceed €83 million, plus expert costs. See our latest analysis for Heineken. At a share price of €71.14, Heineken has a 90 day share price return of 4.62% and a year to date share price return of 3.10%. Its 1 year total shareholder return of 8.22% and 3 year total shareholder return of 21.47% indicate weaker longer...

Why Banijay Group Is on Investors’ Radar Today Banijay Group (ENXTAM:BNJ), the Paris headquartered content and online gaming group, has recently attracted attention as investors reassess its mix of media production and sports betting operations alongside its current share price. See our latest analysis for Banijay Group. With the share price at €8.40, Banijay Group has seen a 4.35% 7 day share price return and a 3.70% 30 day share price return. The 1 year total shareholder return of 2.27% and...

Why SBM Offshore’s latest earnings are in focus SBM Offshore (ENXTAM:SBMO) has drawn fresh attention after reporting full year 2025 results, confirming higher sales, revenue and net income, along with a new share repurchase program and affirmed dividend plans. See our latest analysis for SBM Offshore. The recent 2025 earnings, fresh €227m buyback program and affirmed dividends sit alongside a 1 month share price return of 8.44% and a 90 day gain of 29.38%, while the 1 year total shareholder...